Company / Operating Income
Inmune Bio, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$42.6M
FY2025
5-year range
-$42.6M / -$12.2M
FY2021-FY2025
Trend
-43.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$26M to -$43M over the past 2 years.
Based on SEC 10-K filings.
-$43M in FY2025.
Declined from -$26M to -$43M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 43.4% year-over-year.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$42.6M | -43.4% |
| FY2024 | -$29.7M | -14.6% |
| FY2023 | -$26.0M | +11.0% |
| FY2022 | -$29.2M | -138.4% |
| FY2021 | -$12.2M | -57.7% |
| FY2020 | -$7.8M | -690.2% |
| FY2018 | -$981.5K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026